Tribal Affairs Min partners with AIIMS for sickle cell treatment
New Delhi, June 19 (UNI) In a major initiative to eradicate Sickle Cell Disease (SCD) by 2047, the Union Ministry of Tribal Affairs has plans to establish excellence centres across 15 leading hospitals and also collaborate with AIIMS, Delhi to launch a national competition aimed at developing new treatment options for this debilitating genetic blood disorder.
With only one drug currently available for SCD management, this collaboration seeks to address the critical need for more effective therapies to combat the disease, which causes chronic anaemia, severe pain, organ damage, and a significantly reduced life expectancy, particularly among India's tribal populations.
"The proposals selected in the competition will receive funding of up to Rs 10 crore for drug development. In parallel, the Ministry is establishing Centers of Competence (CoC) across 15 leading hospitals, including AIIMS, to enhance diagnostic and care facilities for the affected tribal communities," said Union Minister of State for Tribal Affairs, Durgadas Uikey, during the World Sickle Cell Day event at AIIMS here on Thursday.
Following the Prime Minister's announcement on July 1, 2023 to eliminate Sickle Cell Anemia from India by 2047, the Ministry has already initiated nationwide screening and testing programs aimed at combating the disease.
Vibhu Nayar, Secretary of the Ministry of Tribal Affairs, emphasised that the CoCs aims to offer state-of-the-art diagnostic and management services for SCD, including ante-natal care. These centers, which will be operational by November 2023, will also facilitate referrals and provide specialized care to patients across the country.
Nayar further stated that one of the proposed centers may serve as a national reference point for tribal health at AIIMS, Delhi which could aid hospitals in tribal-dominated regions and explore the causes of malnutrition and its potential links to genetic factors.
'One national specialize reference center on tribal health could be set up in AIIMS New Delhi which could provide assistance to the hospitals located in tribal dominated areas in different states and districts, it could provide clues why malnutrition is occurring despite several measures, it has to examine whether it's the genetic or any other reason,' the secretary added.
At the event, Minister Durgadas Uikey also interacted with patients of sickle cell anaemia and their families. As people from different parts of the country are currently residing and receiving treatment in Delhi, the Minister assured them of all support of Central and state governments. He also assured them about the free availability of all medicines associated with the management of SCD.
UNI AJ RKM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India Today
2 hours ago
- India Today
Health ministry probes AIIMS Bhopal over irregularities in medicine purchases
A team of officials from the Union Health Ministry visited AIIMS Bhopal to examine documents related to medicine procurement, following allegations by Bhopal MP Alok Sharma that the institute purchased medicines at inflated the matter was raised before the AIIMS Standing Committee on Finance during a meeting in Delhi. The central team arrived at AIIMS Bhopal on Thursday morning and examined documents related to the purchase of medicines. The team also met the Director of the institute and enquired about the purchase process. advertisement The institute has been accused of purchasing medicines directly without following the rules of the central government. In his complaint, Bhopal MP Alok Sharma mentioned that the prices of medicines purchased by AIIMS Bhopal are much more expensive than the AIIMS of other states. Sharma, who is also a member of the AIIMS standing committee, said that he had received a complaint that the injection of Gemcitabine was purchased by Bhopal AIIMS at Rs 2100 per piece, whereas it was purchased at Rs 425 by Raipur AIIMS of Chhattisgarh. Its price in Delhi AIIMS is Rs 285 per piece. The prices of other medicines were also found to be higher. "On May 15, a meeting of the AIIMS standing committee was held in New Delhi in the presence of Union health secretary Punya Salila Shrivastava. In the meeting, I complained regarding the high prices of medicines being purchased by AIIMS Bhopal. She assured me that an investigation will be conducted," said Sharma. advertisementHe also said that like other government hospitals, medicines are bought through tender in AIIMS. However, during the Covid-19 period, direct purchase of medicines was approved. "However, despite the end of the Covid-19 period, direct purchase of medicines continued and the figure of purchased medicines reached crores," he added. Must Watch
Time of India
2 hours ago
- Time of India
IIT Guwahati develops mechanism to treat 1,000 litre contaminated water for Rs 20
New Delhi: Researchers at Indian Institute of Technology (IIT), Guwahati, have developed a low-cost community scale water treatment system that removes fluoride and iron from groundwater and can treat up to 20,000 litre of contaminated water per day, officials said. The findings of the research have been published in the prestigious ACS ES&T Water journal. The researchers claimed the system was highly affordable and could treat 1,000 litre of water at a paltry Rs 20. According to Mihir Kumar Purkait, Professor at Department of Chemical Engineering, IIT Guwahati , fluoride, a mineral generally used in dental care products, pesticides, fertilisers and some industrial processes, can enter groundwater either naturally or through human activities such as agriculture and manufacturing. "Consumption of water with excess fluoride presence can lead to skeletal-fluorosis, a serious health condition in which bones harden and joints become stiff, making physical movement difficult and painful. In India, states including Rajasthan, Telangana, Andhra Pradesh, Karnataka, Haryana, and Gujarat, among others, face high levels of fluoride in groundwater," Purkait said. The IIT Guwahati research team developed a four-step system that ensures a cost-effective and energy-efficient technology for contaminated water treatment. Purkait said the hydrogen and oxygen bubbles produced during electrolysis interact with air bubbles, assisting in lifting pollutant particles to the surface. The selection of electrode material depends on factors like low cost, low oxidation potential and high electro-positivity after dissolution. "Among available options, aluminum has proven highly effective, particularly in the removal of iron, arsenic, and fluoride under optimal operational conditions," he said. The research team tested the developed system under real-world conditions for 12 weeks and recorded consistent performance. The results have shown removal of 94 per cent iron and 89 per cent fluoride from the wastewater, bringing the levels within safe limits set by Indian standards. "A key feature of the developed system is its cost effectiveness, with Rs 20 per 1,000 liters of treated water, making it highly affordable. The developed technology requires minimal supervision and has a projected lifespan of 15 years with electrode replacement scheduled every six months," he said. The study proposes a method to estimate electrode life using a built-in safety factor to ensure timely maintenance. As a pilot project, in support with the Public Health Engineering Department of Assam, the developed technology has been successfully installed by Kakati Engineering Pvt Ltd in Changsari, Assam. "We are also exploring the use of solar or wind power to operate the unit and to utilise the hydrogen gas generated during electrocoagulation process . By integrating smart technologies such as real-time sensors and automated controls, we will be able to further reduce the need for manual intervention, making the system more effective for remote and underserved areas," he said. The research team also aims to combine the current system with other water treatment methods to enhance performance and provide a decentralised water treatment solution. PTI
Time of India
2 hours ago
- Time of India
Inquiry committee submits report on VS illegal trials to Ahmedabad municipal commissioner
Ahmedabad: A five-member AMC committee completed its investigation into the alleged illegal clinical trials at VS Hospital and submitted a report, implicating top doctors in a multi-crore scam. Between 2021 and 2025, 58 unauthorized trials were conducted on over 500 patients in complete violation of rules, with payments from pharmaceutical companies routed to the accounts of senior doctors, instead of the hospital, said sources citing the report. The panel, led by the head of the AMC vigilance department, has reportedly recommended disciplinary action against all responsible parties. The municipal commissioner is now reviewing the report to decide whether a police complaint should be filed. Sources citing the inquiry report, which includes a 30-page summary and 500 pages of annexures, said that the key accused include then superintendent Dr Manish Patel, clinical head Dr Devang Rana, and contract doctor Dhaivat Shukla. "The trio allegedly siphoned off between Rs 17 crore to Rs 20 crore from pharmaceutical companies into their personal and family accounts. In some cases, money was also deposited into the accounts of unrelated individuals," revealed a source close to the development. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Memperdagangkan CFD Emas dengan salah satu spread terendah? IC Markets Mendaftar Undo The scam came to light after Rajshree Kesari, a Congress councillor from Chandkheda, filed a complaint, alleging that doctors were conducting illegal trials and depositing the money into private bank accounts. After conducting a preliminary investigation, the municipal commissioner then formed a special five-member inquiry panel on April 19. However, after questions were raised about one panel member's credibility, AMC's in-charge health officer Dr Bhavin Solanki was included in the committee. The probe was overseen by Hina Bhathawala, AMC's vigilance department chief. Earlier, eight doctors, including Dr Rana, were suspended, and a notice was served to the retired hospital superintendent. The committee also recorded statements from Dr Patel, Dr Rana, and other implicated personnel. A source, citing the inquiry report, said, "Over four years, 58 pharmaceutical companies conducted various unregulated vaccine and drug clinical research on more than 500 patients. The companies legally paid Rs 17 to 20 crore, none of which reached the hospital's official accounts. Instead, they were deposited into accounts belonging to Dr Patel, Dr Rana, Dr Shukla, their spouses, and even family HUF accounts. Some payments were allegedly made in cash. "The clinical trials were allegedly conducted using the approval of a private ethical committee instead of seeking clearance from the AMC, the hospital's management board, or the Medical Education Trust." Documents pertaining to these trials were either poorly maintained or deliberately concealed, said sources, drawing from the report. Despite a claim from Dr Patel that Rs 6 crore was deposited into the hospital account, the committee found no supporting documentation.
